|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Robust filtering under randomly varying sensor delay with variance constraints显示文摘 | Z.Wang D.Ho X.Liu | | 0，，： | 1 |
| 2 | Effect of interorganizational Team work on Project Outcome显示文摘 | P Chart D.Ho C.Tam | | 0，，： | 1 |
| 3 | Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance显示文摘 | Van ThanhHoang AbrahamZepeda‐Moreno Anthony D.Ho | 2012 | Biotechnology Journal2012，，6： | 1 |
| 4 | Effect of inter-organizational Team work on Project Outcome显示文摘 | P Chart D.Ho C.Tam | | 0，，： | 1 |
| 5 | An evaluation of the algorithms for determining local cerebral metabolic rates of glucose using positron emission tomography dynamic data显示文摘 | D.Feng D.Ho K.Chen L.C.Wu | | 0，，04： | 1 |
| 6 | Developing one-dimensional implosions for inertial confinement fusion science显示文摘Experiments on the National Ignition Facility show that multi-dimensional effects currently dominate the implosion performance. Low mode implosion symmetry and hydrodynamic instabilities seeded by capsule mounting features appear to be two key limiting factors for implosion performance. One reason these factors have a large impact on the performance of inertial confinement fusion implosions is the high convergence required to achieve high fusion gains.To tackle these problems, a predictable implosion platform is needed meaning experiments must trade-off high gain for performance. LANL has adopted three main approaches to develop a one-dimensional(1D) implosion platform where 1D means measured yield over the 1D clean calculation. A high adiabat, low convergence platform is being developed using beryllium capsules enabling larger case-to-capsule ratios to improve symmetry. The second approach is liquid fuel layers using wetted foam targets. With liquid fuel layers, the implosion convergence can be controlled via the initial vapor pressure set by the target fielding temperature. The last method is double shell targets. For double shells, the smaller inner shell houses the DT fuel and the convergence of this cavity is relatively small compared to hot spot ignition. However,double shell targets have a different set of trade-off versus advantages. Details for each of these approaches are described. | J.L.Kline S.A.Yi A.N.Simakov R.E.Olson D.C.Wilson G.A.Kyrala T.S.Perry S.H.Batha E.L.Dewald J.E.Ralph D.J.Strozzi A.G.MacPhee D.A.Callahan D.Hinkel O.A.Hurricane R.J.Leeper A.B.Zylstra R.R.Peterson B.M.Haines L.Yin P.A.Bradley R.C.Shah T.Braun J.Biener B.J.Kozioziemski J.D.Sater M.M.Biener A.V.Hamza A.Nikroo L.F.Berzak Hopkins D.Ho S.LePape N.B.Meezan D.S.Montgomery W.S.Daughton E.C.Merritt T.Cardenas E.S.Dodd | 2016 | High Power Laser Science and Engineering2016，4，4： | 0 |
| 7 | Comments on ‘An airway organoid-based screen identifies a role for the HIF1α‒glycolysis axis in SARS-CoV-2 infection’显示文摘Coronavirus disease 2019(COVID-19)has been an ongoing public health crisis since the end of 2019;besides vaccine development,there have been major research efforts focused on developing antiviral therapeutics.Remdesivir was the first US Food and Drug Administration(FDA)-approved antiviral drug for COVID-19.Subsequently,the FDA granted emergency use authorization(EUA)for three monoclonal antibody treatments,including sotrovimab or a combination of casirivimab and imdevimab,or bamlanivimab and etesevimab,each of which targets the coronavirus spike protein to block viral entry.Most recently,Britain granted conditional authorization for the ribonucleoside analog molnupiravir,developed by Merck as a viral replication inhibitor.The protease inhibitor PF-07321332 developed by Pfizer and boosted by ritonavir showed promising results in a phase III clinical trial,reducing the risk of hospitalization or death by 89%compared with placebo. | Xiaohua Duan Hui Wang David D.Ho Robert E.Schwartz Todd Evans Shuibing Chen | 2022 | Journal of Molecular Cell Biology2022，14，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员